Tozinameran - fractional dose

BIOLOGICAL2 trials

Sponsors

Murdoch Childrens Research Institute

Conditions

COVID-19

Phase 3

Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).

TerminatedNCT05228730

Murdoch Childrens Research InstituteCOVID-19

Start: 2022-05-02End: 2022-11-30Updated: 2024-12-16

Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.

CompletedNCT05265065

Murdoch Childrens Research InstituteCOVID-19

Start: 2022-05-27End: 2024-11-06Updated: 2026-03-24

Related Papers

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial

Frontiers in Immunology2026-03-23

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial.

2025-10-09

Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

2023-11-217 citations